Cargando…

Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: A promising biomarker and therapeutic target for pancreatic cancer

PAM4 is a monoclonal antibody showing high specificity for pancreatic ductal adenocarcinoma (PDAC). Humanized PAM4 labeled with (90)Y in combination with low-dose gemcitabine has shown promising therapeutic activity, and is being evaluated in a phase III clinical trial. Prior efforts have suggested...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Donglin, Chang, Chien-Hsing, Gold, David V., Goldenberg, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414189/
https://www.ncbi.nlm.nih.gov/pubmed/25595893

Ejemplares similares